Lancet:抗病毒治疗是否可以减少HIV相关的结核病发病率?

2015-05-18 崔倩 译 MedSci原创

背景:长期接受抗逆转录病毒疗法(ART)的艾滋病病毒感染者的结核病发病率是否仍高于背景人口率还不清楚。因此研究人员比较了在英格兰、威尔士和北爱尔兰的背景人口率接受ART治疗的人的结核病发病率。    方法:研究人员分析了国家结核病登记的艾滋病毒阳性患者。在HIV阳性人群中(2007-11),结核病发病率通过人种、接受ART的时间以及与背景率(2009年)比较进行分层。

背景:长期接受抗逆转录病毒疗法(ART)的艾滋病病毒感染者的结核病发病率是否仍高于背景人口率还不清楚。因此研究人员比较了在英格兰、威尔士和北爱尔兰的背景人口率接受ART治疗的人的结核病发病率。
    
方法:研究人员分析了国家结核病登记的艾滋病毒阳性患者。在HIV阳性人群中(2007-11),结核病发病率通过人种、接受ART的时间以及与背景率(2009年)比较进行分层。族群被定义如下:黑色非洲人群体包括非洲黑人血统的所有个人,包括那些出生在英国和海外的人;白族群包括出生在英国和海外的所有白色个人;南亚组包括那些印度,巴基斯坦,孟加拉国,出生在英国和海外的;其他族群包括所有其他族裔,包括非裔加勒比黑人。
    
发现:艾滋病毒阳性人群有79919人,在观察的这些年231664个人中有1550例结核发生(每年每1000人有6.7个病例)。其中,非洲黑人在HIV阳性人群中每年每1000人的结核病发病率为13.6%,白人为1.7%。非洲黑人HIV患者长期ART治疗(≥5年)的结核发病率为每年每1000人中有2.4例,类似于背景率的每年每1000人中的1.9%(率比1.2 ,95%Cl 0.96-1.6;P=0.083);但白人HIV患者并长期接受ART治疗的发病率为每年每1000人为0.5,比背景率的0.04要高(率比14.5 9.4-21.3,P<0.0001)。当分析仅限于个人ART时间累计至CD4细胞计数每微升至少500个以及在国外出生的白人HIV阳性者被排除在外时,相对白人HIV阳性个体的发病率是持续增加的。
    
结论:不管非洲黑人的艾滋病毒状况如何,结核病高发病率都是不可接受的。在白人HIV感染者中,尽管长期接受ART治疗,结核病发病率比背景发生率显著较高。暂且不论接受ART治疗状况和CD4细胞计数,扩大检测和治疗所有艾滋病毒感染的成年人潜伏性结核感染都是必要的。

原始出处:

Dr Rishi K Gupta, MRCPcorrespondenceemail, Brian Rice, MSc, Alison E Brown, PhD, H Lucy Thomas, MFPH, Dominik Zenner, MD, Laura Anderson, PhD, Debora Pedrazzoli, MSc, Anton Pozniak, MD, Prof Ibrahim Abubakar, FRCP, Valerie Delpech, FFPH†, Marc Lipman, MD†,Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland,Lancet,2015.5.17

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823238, encodeId=7b0a182323847, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Sep 01 10:32:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828111, encodeId=7f601828111d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253955, encodeId=1fee125395515, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292326, encodeId=52a2129232674, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292798, encodeId=1f781292e981b, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24057, encodeId=04562405e42, content=双重感染发生在什么阶段?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Mon May 18 16:12:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823238, encodeId=7b0a182323847, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Sep 01 10:32:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828111, encodeId=7f601828111d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253955, encodeId=1fee125395515, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292326, encodeId=52a2129232674, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292798, encodeId=1f781292e981b, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24057, encodeId=04562405e42, content=双重感染发生在什么阶段?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Mon May 18 16:12:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2015-11-11 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823238, encodeId=7b0a182323847, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Sep 01 10:32:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828111, encodeId=7f601828111d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253955, encodeId=1fee125395515, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292326, encodeId=52a2129232674, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292798, encodeId=1f781292e981b, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24057, encodeId=04562405e42, content=双重感染发生在什么阶段?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Mon May 18 16:12:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1823238, encodeId=7b0a182323847, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Sep 01 10:32:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828111, encodeId=7f601828111d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253955, encodeId=1fee125395515, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292326, encodeId=52a2129232674, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292798, encodeId=1f781292e981b, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24057, encodeId=04562405e42, content=双重感染发生在什么阶段?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Mon May 18 16:12:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2015-05-20 yahu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1823238, encodeId=7b0a182323847, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Sep 01 10:32:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828111, encodeId=7f601828111d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253955, encodeId=1fee125395515, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292326, encodeId=52a2129232674, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292798, encodeId=1f781292e981b, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24057, encodeId=04562405e42, content=双重感染发生在什么阶段?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Mon May 18 16:12:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1823238, encodeId=7b0a182323847, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Sep 01 10:32:00 CST 2015, time=2015-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828111, encodeId=7f601828111d6, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Nov 11 22:32:00 CST 2015, time=2015-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253955, encodeId=1fee125395515, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292326, encodeId=52a2129232674, content=<a href='/topic/show?id=a3b4554e19d' target=_blank style='color:#2F92EE;'>#抗病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55471, encryptionId=a3b4554e19d, topicName=抗病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=52c7237, createdName=yahu, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292798, encodeId=1f781292e981b, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55479, encryptionId=9d23554e95a, topicName=抗病毒治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ce4238, createdName=dangious, createdTime=Wed May 20 05:32:00 CST 2015, time=2015-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24057, encodeId=04562405e42, content=双重感染发生在什么阶段?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9e0b1603164, createdName=lovejing, createdTime=Mon May 18 16:12:00 CST 2015, time=2015-05-18, status=1, ipAttribution=)]
    2015-05-18 lovejing

    双重感染发生在什么阶段?

    0

相关资讯

WJG:抗病毒治疗对肝脏肿瘤形成和肝癌再发的影响

治疗用抗病毒药物如作为核苷(酸)类似物(Nucs)或干扰素(IFN)-α可以迅速抑制HBV复制,从而减少纤维化的进展和HCC的发生。虽然局部或全身的化疗可以治疗肿瘤,但手术切除或肝移植仍是治疗HCC的最有效方法。术后HCC复发是常见的现象。预防乙肝相关性肝癌的发生和复发需要接受综合性治疗,这一观点已得到广泛的认识。 因此,来自南京医科大学附属第一医院的研究人员综述了HBV诱导肝癌的机制,讨论

中国艾滋病疫苗已完成二期临床研究

首都医科大学附属北京佑安医院科主任吴昊1日在介绍治疗艾滋病的新突破时指出,中国的疫苗研制进度很快。目前,在佑安医院已经完成了二期临床研究。 国家卫生计生委1日组织在线访谈,介绍中国艾滋病防治工作进展、疫情情况、面临的主要困难和挑战及下一步工作内容。邀请国家卫生计生委疾病预防控制局副局长夏刚、中国疾控中心性病艾滋病预防控制中心主任吴尊友、首都医科大学附属北京佑安医院科主任吴昊与网友互动交流。 就

丙肝肝移植患者抗病毒治疗新方案—更快、更安全

接受肝移植的丙肝患者的新肝组织最终都会出现感染。在这些移植的组织严重受损前需进行抗病毒治疗,但是传统的移植后治疗时间长达一年,存在潜在毒性并且可能导致器官排斥反应。最近,在美国肝病研究协会(The Liver Meeting® 2014)上,梅奥诊所的研究者报道:肝移植后采用两种新的口服药物治疗,安全有效并且治疗只需12周即可完成。该项研究的负责人Pungpapong博士说:“该研究是首个在肝移植

26天20例人感染H7N9禽流感死亡病例

1月26日,国家卫生计生委召开的人感染H7N9禽流感防控采访会上,中疾控、国家流感中心专家表示,因无证据显示H7N9人和人之间大规模传播,预判春节人员流动不会造成疫情暴发。 据新华社统计,1月1日至26日,全国已确诊人感染H7N9禽流感病例96例,浙粤沪三省份确诊83例,死亡20例,其中浙江死亡12例,广东死亡4例,上海死亡4例,包括1名医务人员。 专家认为,H7N9病死率较高

英国科学家发现抗艾滋病药物能预防宫颈癌

近日,科学家研究发现宫颈癌可被艾滋病常用药物预防。 曼彻斯特大学的夫妻研究团队研究发现艾滋病药物能够杀死导致宫颈癌的病原体人类乳头瘤病毒。他们发现用洛匹那韦在没有副作用的前提下减少90%的癌前细胞。 这个研究成果将于本月晚些时候在两个会议上发表。科研人员对这个结果非常惊喜,他们表示以后女性可以在家用药预防宫颈癌,而不用忍受活检和外科手术切除宫颈异常的痛苦。 该药的临床试验是在

第二届京港感染医师论坛(2013)开幕

11月15日,第二届”京港感染医师论坛“在京开幕。此次论坛由北京医师协会感染医师分会、首都医科大学附属北京朝阳医院、北京大学人民医院、北京大学第一医院共同主办,香港传染病医学会、The Clinical Respiratory Joural协办,北京协科技术培训中心承办。论坛吸引了多位知名感染病学专家及来自多个省市的500余名临床医师和微生物科同仁参会。北京医师协